{"entity":{"id":"anticancer-bioscience","kind":"company","name":"Anticancer Bioscience","aka":["Chengdu Anticancer Bioscience, Ltd."],"tldr":"Anticancer Bioscience develops tablet medicines meant to kill cancer cells that depend on the MYC gene, chosen with a test for MYC; its first drug has just entered an early trial.","summary":"Chengdu Anticancer Bioscience, Ltd. states that it translates MYC synthetic lethality into biomarker-driven cancer therapies, and lists locations in Chengdu, St Andrews (UK), San Francisco, Sydney and Hyderabad. JMBI-001 tablets are in a phase 1/2 study in adults with MYC-positive advanced cancers, including solid tumours and non-Hodgkin lymphoma (NCT07864701). Its first registered cancer trial, NCT07864701, was posted on ClinicalTrials.gov in October 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.anticancerbio.com/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of JMBI-001 (NCT07864701)","url":"https://clinicaltrials.gov/study/NCT07864701"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches"],"targets":["myc-gene"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website was a holding page on 29 October 2026 ('Our website will be live soon'), stating only the MYC synthetic lethality focus and its locations. Founding year, financing and the mechanism of JMBI-001 beyond the registry title were not available. Treat this record as thin."],"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.anticancerbio.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/anticancer-bioscience/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"}]}}